Dendrimers as Nonviral Vectors in Dendritic Cell-Based Immunotherapies Against Human Immunodeficiency Virus: Steps Toward Their Clinical Evaluation
2014; Future Medicine; Volume: 9; Issue: 17 Linguagem: Inglês
10.2217/nnm.14.172
ISSN1748-6963
AutoresEnrique Vacas‐Córdoba, Núria Climent, F. Javier de la Mata, Montserrat Plana, Rafael Gómez, Marjorie Pion, Felipe García, María Ángeles Muñoz‐Fernández,
Tópico(s)HIV Research and Treatment
ResumoAlthough the antiretroviral therapy has led to a long-term control of HIV-1, it does not cure the disease. Therefore, several strategies are being explored to develop an effective HIV vaccine, such as the use of dendritic cells (DCs). DC-based immunotherapies bear different limitations, but one of the most critical point is the antigen loading into DCs. Nanotechnology offers new tools to overcome these constraints. Dendrimers have been proposed as carriers for targeted delivery of HIV antigens in DCs. These nanosystems can release the antigens in a controlled manner leading to a more potent specific immune response. This review focuses on the first steps for clinical development of dendrimers to assess their safety and potential use in DC-based immunotherapies against HIV.
Referência(s)